Mr. Mike Withrow reports

ABATTIS ANNOUNCES NEGOTIATIONS WITH EXPERION

Abattis Bioceuticals Corp. has begun negotiations with Experion Biotechnologies Inc. regarding a memorandum of understanding (MOU) signed earlier this month relating to the establishment of a collaborative relationship in areas of licensing and consulting.

The MOU will serve as a basis for the negotiation of definitive agreements relating to the future development and implementation by the parties of:

• Good manufacturing processes and standard operating procedures for marijuana medical purposes regulations;
• Establishing Experion as a licensed producer;
• The development and implementation of a means to dispense to clients as put forth in the marijuana medical purposes regulations;
• Licensing;
• Distribution.

The first definitive agreement being negotiated will be for the exchange set out below, conditional upon Experion becoming a licensed producer:

Experion will issue to Abattis the number of shares equal to 15 per cent of its issued and outstanding common shares. The Experion shares are to have dividend rights attached such that Abattis will be entitled to receive a portion of the net profits of Experion pro rata with Abattis's equity ownership in Experion, on an annual basis.

Abattis will issue to Experion 200,000 common shares and the following options:

• 200,000 options exercisable for one year at an exercise price of 10 cents per share;
• 200,000 options exercisable for two years at an exercise price of 20 cents per share;
• 200,000 options exercisable for three years at an exercise price of 30 cents per share

"Our collaborative relationship with Experion is an exciting development for Abattis. Experion has submitted its application to Health Canada and we look forward to it becoming a licensed producer in the near future. Together, we will work toward maximizing the value of that licence for both of our companies and for medical marijuana patients by ensuring high-quality products, strict adherence to the legal regime and mutual support for producing and distributing a reliable, quality product," said Mike Withrow, president and chief executive officer of Abattis. "Experion Biotechnologies is pleased with achieving this first of many milestones with Abattis and we look forward to solidifying our relationship in the very near future," said Sean MacNeil, director of communications for Experion.

We seek Safe Harbor.